The agency is in a "firefighting posture versus a proactive posture" and is "unable to keep up with major scientific advances."

Gail Cassell, PhD, chair of the Science Board, on the current status of the FDA as a regulatory body, "Sparks, big ones, fly as FDA's leadership, science questioned," pp. 1, 7.